

Can bone turnover markers help to define the duration of bisphosphonate drug holidays?

Louise Statham^{1,2}, Sharon Abdy¹, Terry Aspray^{1,3}

¹The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE7 7DN, UK

²University of Sunderland, Dept. of Pharmacy, Health & Well-being, Sunderland, SR1 3SD, UK

³Newcastle University, Institute of Cellular Medicine, Newcastle upon Tyne, NE2 4HH, UK

Background

Good evidence for 5 years bisphosphonate (BP) treatment^{1,2} but beyond this less clear

- BP long half-life; stopping treatment → wears off gradually²

Potential for harm

- Atypical fractures, osteonecrosis of the jaw (ONJ)
- Rare occurrence, ↑risk with increasing duration³

BPs impair Bone Turnover; CTX bone turnover marker (bone resorption)

- Start BP → ↓CTX
- Stop BP & CTX rises²

Drug holidays increasingly common - stop BP for period of time

Local practice since late 2012

- Review BP after 5 yrs
- Drug holiday
- Routine monitoring CTX at baseline, 4 months and 12 months


Our aim was to analyse changes in CTX on stopping long term bisphosphonate treatment to guide clinical decision-making on the duration of treatment cessation

Methods

- Patients on BP drug holiday via outpatient Bone Clinic identified from monitoring records
- Data extracted; patient age, sex, serum CTX levels 0, 4, 12 months, bisphosphonate and duration of use
- Excluded if baseline (0m) CTX ≥0.51 ug/L (higher fracture risk)
- Data analysis using Stata Statistics software.
- Offset of action defined as
 - a rise by the Least Significant Change (LSC=33%*) in CTX and CTX above the pre-menopausal mean (0.19ug/L)

*LSC=2.33xv(CVa²)+(CVi²): CVa is analytical coefficient of variation, CVi is intra-individual CV

Figure 1: All patient characteristics



Mean Patient Age	71 years
Gender	83% female; 17% male
Mean Duration BP	8 years (range 3-15 years)
Alendronic acid	59%
Risedronate	33%
Other Bisphosphonate	8%

Results




Figure 2: CTX at 0, 4, 12 months all patients (<0.51 at baseline)





Figure 3: CTX at 0, 4, 12 months for defined populations



Overall population (figure 2):

- Detectable rise in CTX seen from as early as 4 months in 47% patients; 69% at 12 months

Subpopulations (figure 3):

- If CTX ≤ pre-menopausal mean (i.e. treatment target) at baseline, statistically significant increases in CTX seen at 4 and 12 months
- If CTX > pre-menopausal mean at baseline, no significant change at 4 months, significant by 12 months
- No significant difference between Alendronic acid and Risedronate seen (data not shown)


Monitoring outcomes using population data (figure 4):

- Baseline CTX not suppressed to premenopausal mean level after 5 yrs of BP use in 32% patients

• Where CTX suppressed at baseline:

- At 4 months 28% had significant rise in CTX that was also above mean level (?consider re-start)
- At 12 months this had risen to 53%; 47% CTX still suppressed at this stage

Figure 4: CTX monitoring outcomes at baseline, 4 and 12 months



*Mean premenopausal CTX 0.19 ug/L(0.05-0.63)⁴

Conclusion

- After at least 5 years of treatment, CTX may not be adequately suppressed in a third of patients. Drug adherence and therapy choice should be reviewed in this group.
- Less significant changes in CTX seen if levels not adequately suppressed at baseline ?adherence
- Treatment effects can wear off as quickly as 4 months, but may also be maintained for 12 months
- Monitoring of CTX can potentially be used to identify these patients, some of whom may need to re-start treatment earlier

References

- 1.Sorensen OH *et al* (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. *Bone*;32(2):120-6.
- 2.Black DM *et al* (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. *JAMA* ; 296; 24:2927-2938;
- 3.MHRA Drug Safety Update June 2011, vol 4 issue 11: A1;
4. Gossiel F *et al* (2014) Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state. *BoneKey Reports* 3, article no: 573.

Conflicts of interest: None declared